NUMD
Nu-Med Plus, Inc. [NUMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NUMD Stock Summary
In the News
NUMD Financial details
Company Rating
Neutral
Market Cap
1.42M
Income
-104.18K
Revenue
0
Book val./share
-0
Cash/share
0
Dividend
-
Dividend %
-
Employees
2
Optionable
No
Shortable
Yes
Earnings
31 Mar 2023
P/E
-13.66
Forward P/E
-
PEG
1.8
P/S
-
P/B
-15.6
P/C
-
P/FCF
-30.61
Quick Ratio
0.38
Current Ratio
0.39
Debt / Equity
-1.65
LT Debt / Equity
-
-
-
EPS (TTM)
-0
EPS next Y
-
EPS next Q
-
EPS this Y
-85.71%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-55.56%
-
-
-
-
SMA20
-
SMA50
-
SMA100
-50%
Inst Own
-
Inst Trans
-
ROA
-176%
ROE
62%
ROC
1.64%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
81.35M
Shs Float
0
-
-
-
-
Target Price
-
52W Range
0.009-0.0731
52W High
-
52W Low
-
RSI
71.61
Rel Volume
0.58
Avg Volume
18.04K
Volume
10.5K
Perf Week
34.62%
Perf Month
25%
Perf Quarter
-21.35%
Perf Half Y
-31.37%
-
-
-
-
Beta
0.76988
-
-
Volatility
0%, 0%
Prev Close
25%
Price
0.0175
Change
16.67%
NUMD Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.03 | -0.02 | -0.04 | -0.01 | 0 | |
| Operating cash flow per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
| Free cash flow per share | -0.01 | -0.01 | -0.01 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | -0.01 | 0.01 | 0 | 0 | |
| Tangible book value per share | 0 | -0.01 | 0.01 | 0 | 0 | |
| Share holders equity per share | 0 | -0.01 | 0.01 | 0 | 0 | |
| Interest debt per share | 0.01 | 0.01 | 0 | 0 | 0 | |
| Market cap | 31.34M | 20.5M | 49.06M | 2.57M | 1.32M | |
| Enterprise value | 31.41M | 20.73M | 48.89M | 2.56M | 1.35M | |
| P/E ratio | -26.36 | -19.44 | -24.25 | -3.13 | -10.06 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -67.03 | -36.13 | -118.28 | -12.42 | -34.28 | |
| PFCF ratio | -66.31 | -36.13 | -118.28 | -12.42 | -34.28 | |
| P/B Ratio | 645.81 | -55.33 | 104.9 | -19.4 | -20.93 | |
| PTB ratio | 645.81 | -55.33 | 104.9 | -19.4 | -20.93 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -27.21 | -20.83 | -24.81 | -3.13 | -7.84 | |
| EV to operating cash flow | -67.18 | -36.53 | -117.87 | -12.4 | -34.98 | |
| EV to free cash flow | -66.47 | -36.53 | -117.87 | -12.4 | -34.98 | |
| Earnings yield | -0.04 | -0.05 | -0.04 | -0.32 | -0.1 | |
| Free cash flow yield | -0.02 | -0.03 | -0.01 | -0.08 | -0.03 | |
| Debt to equity | 7.72 | -1.12 | 0.19 | -1.17 | -2.26 | |
| Debt to assets | 0.89 | 9.09 | 0.16 | 6.97 | 1.79 | |
| Net debt to EBITDA | -0.06 | -0.23 | 0.09 | 0 | -0.16 | |
| Current ratio | 1.03 | 0.03 | 6.72 | 0.08 | 0.56 | |
| Interest coverage | -59.85 | -58.57 | -139.27 | 89.45 | -182.17 | |
| Income quality | 0.39 | 0.55 | 0.21 | 0.25 | 0.3 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0.01 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | -0.34 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.03 | 0.07 | 0.08 | 0.02 | 0.01 | |
| ROIC | -16.2 | 46.51 | -14.98 | 15.11 | 1.69 | |
| Return on tangible assets | -2.81 | -23.03 | -3.63 | -37.03 | -1.65 | |
| Graham Net | 0 | -0.01 | 0 | 0 | 0 | |
| Working capital | 11.74K | -402.25K | 457.48K | -142.85K | -63.03K | |
| Tangible asset value | 48.53K | -370.43K | 467.7K | -132.36K | -63.03K | |
| Net current asset value | 11.74K | -402.25K | 448.09K | -142.85K | -63.03K | |
| Invested capital | 4.97 | -0.64 | 0.04 | -0.06 | -1.59 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 9.89K | 34.84K | 49.98K | 49.9K | 47.66K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 1.17K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0.31 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -24.5 | 2.85 | -4.33 | 6.2 | 2.08 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-03-31 for Q1
| Metric | History | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | 0 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | 0 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | 0 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 1.75M | 1.34M | 2.19M | 1.32M | 1.47M | |
| Enterprise value | 1.75M | 1.34M | 2.19M | 1.35M | 1.52M | |
| P/E ratio | -8.13 | -5.77 | -9.44 | 7.74 | -11.97 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -143.82 | -528.57 | 3.49K | -53.99 | -72.81 | |
| PFCF ratio | -143.82 | -528.57 | 3.49K | -53.99 | -72.81 | |
| P/B Ratio | -9.24 | -5.43 | -8.12 | -20.93 | -16.1 | |
| PTB ratio | -9.24 | -5.43 | -8.12 | -20.93 | -16.1 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -30.38 | -24.52 | -39.17 | -396.7 | -56.18 | |
| EV to operating cash flow | -144.03 | -529.38 | 3.49K | -55.09 | -75.14 | |
| EV to free cash flow | -144.03 | -529.38 | 3.49K | -55.09 | -75.14 | |
| Earnings yield | -0.03 | -0.04 | -0.03 | 0.03 | -0.02 | |
| Free cash flow yield | -0.01 | 0 | 0 | -0.02 | -0.01 | |
| Debt to equity | -1.04 | -1.03 | -1.01 | -2.26 | -1.65 | |
| Debt to assets | 24.85 | 30.28 | 86.27 | 1.79 | 2.54 | |
| Net debt to EBITDA | -0.05 | -0.04 | 0.01 | -7.9 | -1.74 | |
| Current ratio | 0.04 | 0.02 | 0.01 | 0.56 | 0.39 | |
| Interest coverage | 19.88 | 0 | 0 | -6.39 | -21.87 | |
| Income quality | 0.21 | 0.04 | -0.01 | -0.57 | 0.72 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.01 | 0.01 | 0.01 | 0 | 0 | |
| ROIC | 0.75 | 0.53 | 0.46 | 0.06 | 0.31 | |
| Return on tangible assets | -6.77 | -6.88 | -18.32 | 0.54 | -0.52 | |
| Graham Net | 0 | 0 | 0 | 0 | 0 | |
| Working capital | -189.26K | -249.17K | -270.13K | -63.03K | -91.23K | |
| Tangible asset value | -189.01K | -247.08K | -270.13K | -63.03K | -91.23K | |
| Net current asset value | -189.26K | -249.17K | -270.13K | -63.03K | -91.23K | |
| Invested capital | -0.03 | -0.01 | 0 | -1.59 | -1.1 | |
| Average receivables | 0 | 0 | 0 | 0 | 1.75K | |
| Average payables | 65.99K | 98.58K | 123.83K | 85.16K | 44.82K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 1.71K | 7.43K | 0 | 1.31K | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0.05 | 0.01 | 0 | 0.07 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | 0.28 | 0.24 | 0.21 | -0.68 | 0.34 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
NUMD Frequently Asked Questions
What is Nu-Med Plus, Inc. stock symbol ?
Nu-Med Plus, Inc. is a US stock , located in Salt lake city of Ut and trading under the symbol NUMD
What is Nu-Med Plus, Inc. stock quote today ?
Nu-Med Plus, Inc. stock price is $0.0175 today.
Is Nu-Med Plus, Inc. stock public?
Yes, Nu-Med Plus, Inc. is a publicly traded company.
Company Profile
- Volume Average 18.04K
- Market Capitalization 1.42M
- Employee 2
- CEO Mr. William Charles Hayde
- Headquarters Salt Lake City,UT,US
- IPO Date 2014-09-25
-
Website
https://www.nu-medplus.com 
Nu-Med Plus, Inc., a medical device company, engages in the design, development, enhancement, and commercialization of medical devices worldwide. It develops a hospital nitric oxide delivery system, a clinical nitric oxide delivery system, a mobile rechargeable device to deliver nitric oxide gas, and a nitric oxide system that can be used for research applications. The company serves hospitals, health systems, and the medical community. Nu-Med Plus, Inc. was incorporated in 2011 and is headquartered in Salt Lake City, Utah.
